HIGHFDA DRUG

Glenmark Carvedilol 3.125 mg Recall for Nitrosamine Impurity Affects 44,328 Bottles (2025)

Glenmark Pharmaceuticals Inc. recalls 44,328 bottles of Carvedilol tablets, 3.125 mg, distributed nationwide in the USA. The impurity N-nitroso carvedilol I exceeds the Acceptable Intake Level. Consumers should stop using the product and contact Glenmark for guidance.

Official notice

Source-backed recall notice

No product image was available from the source feed.

Official source
FDA DRUG
Recall date
August 7, 2025
Status
ACTIVE
Severity
8/10

Quick Facts at a Glance

Recall Date
August 7, 2025
Hazard Level
HIGH
Brands
Glenmark Pharmaceuticals, CARVEDILOL
Category
Health & Personal Care
Sold At
Unknown
Geographic Scope
1 states
At-Risk Groups
GENERAL, PREGNANT, PREGNANT

What to Do Now

Use this page like a recall checklist: verify the product first, then act on the official remedy.

Immediate steps

  1. 1Stop using the product until you confirm whether it is included in the recall.
  2. 2Compare the product label, model number, UPC, color, size, and purchase location against the identifiers below.
  3. 3Follow the official remedy from FDA - Drug Safety; save photos, receipts, labels, and correspondence before contacting the company.
  4. 4If the product could harm a child, older adult, pet, or patient, move it out of reach immediately.

Check these identifiers

Brand
Glenmark Pharmaceuticals, CARVEDILOL
Product type
Carvedilol Tablets
Model numbers
NDC 68462-162-05, NDC 68462-162-01, Lot#: 19242274, Lot#: 19242275, Lot#: 19242272, Exp: 5/31/20, Exp: 5/31/2026
UPC codes
68462-162, 68462-163, 68462-164, 68462-165, 68462-162-60, 68462-162-01, 68462-162-18, 68462-162-05 +6 more
Sizes
500-count, 100-count
Sold at
Unknown
Where affected
ALL

Recall Timeline

Key dates and source checks for this recall record.

  1. Recall announced

    August 7, 2025

  2. Reported by FDA DRUG

    August 20, 2025

  3. RecallRadar source check

    April 18, 2026

  4. Consumer action

    Use the official remedy and keep documentation.

Hazard Information

CGMP Deviations: Presence of a nitrosamine, N-Nitroso Carvedilol I Impurity above the current Acceptable Intake Level.

What You Should Do

Consumers and healthcare providers should stop using this product immediately. Contact Glenmark Pharmaceuticals Inc., USA or your healthcare provider for guidance. Notification method: Letter

About This Product

Carvedilol is used to treat high blood pressure and heart failure. This 3.125 mg dose comes in standard Rx packaging.

Why This Is Dangerous

Nitrosamines are potential carcinogens. The impurity exceeds acceptable intake levels, prompting CGMP deviations in manufacturing.

Industry Context

This recall is part of ongoing CGMP-related nitrosamine surveillance in regulated drug manufacturing.

Real-World Impact

The recall affects patients who rely on carvedilol for cardiovascular conditions, requiring them to stop use and seek medical guidance.

Practical Guidance

How to identify if yours is affected

  1. 1. Locate the bottle NDC on the label (68462-162-05 or 68462-162-01).
  2. 3. Confirm packaging type (500-count or 100-count bottle).

Where to find product info

FDA recall page and Glenmark patient letters; label details on each bottle.

What timeline to expect

Refund/replacement timelines vary; check with Glenmark for specifics.

If the manufacturer is unresponsive

  • Document all attempts to contact Glenmark.
  • File a MedWatch adverse event report if you experience symptoms.
  • Consult your pharmacist for interim treatment guidance.

How to prevent similar issues

  • Verify CGMP compliance when choosing generic carvedilol.
  • Ask healthcare providers about nitrosamine-related recalls.
  • Keep updated with FDA recall notices.

Documentation advice

Retain recall notices, label copies, and pharmacy communications; document dates and contacts.

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

Product Details

Product: Carvedilol Tablets, USP 3.125 mg. Packaging: 500-count bottle NDC 68462-162-05; 100-count bottle NDC 68462-162-01. Rx only. Manufactured by Glenmark Pharmaceuticals Ltd, Colvale-Bardez Goa, India. Manufactured for Glenmark Pharmaceuticals, Inc., Mahwah, NJ, USA. Quantity: 44,328 bottles. Sold nationwide in the USA.

Reported Incidents

No specific injuries or incidents are reported in the dataset.

Key Facts

  • Manufactured in India for US distribution
  • Nitrosamine impurity exceeding intake guidelines
  • Recall status: ACTIVE

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: What to Do When You Find a Recalled Product

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
8/ 10
Affected Groups
GENERALPREGNANTPREGNANTPREGNANTPREGNANT
Injury Types
POISONINGELECTRICAL

Product Details

Model Numbers
NDC 68462-162-05
NDC 68462-162-01
Lot#: 19242274
Lot#: 19242275
Lot#: 19242272
+2 more
UPC Codes
68462-162
68462-163
68462-164
+11 more
Affected States
ALL
Report Date
August 20, 2025
Source Agency
FDA - Drug Safety
Recall Status
ACTIVE

Related Recalls